Electrolytic substance infusion device

Information

  • Patent Grant
  • 6738662
  • Patent Number
    6,738,662
  • Date Filed
    Tuesday, November 21, 2000
    24 years ago
  • Date Issued
    Tuesday, May 18, 2004
    20 years ago
  • Inventors
  • Examiners
    • Casler; Brian L.
    • Thissell; Jeremy
    Agents
    • Welsh & Flaxman LLC
Abstract
A portable, self-contained hand-held device for treating an illness or infection of tissue of a body is provided. The device comprises an integrally mounted metal ion source contactable with the tissue with an antimicrobial substance on at least a portion of the metal ion source. A conducting surface is contactable with the user. An automatically controlled and modulated field electrically is connected to the metal ion source and the conducting surface with the control system creating an electric field between the metal ion source and the conducting surface through the body wherein the antimicrobial substance is ionized upon application of the electric field thereby profusing the substance into the infected tissue. In another embodiment, a bandage is provided for adhering to the skin of the user.
Description




BACKGROUND OF THE INVENTION




1. Field of the Invention




This invention relates generally to a treatment device for application to body tissue for treatment of injuries and illnesses and, more particularly, it relates to a treatment device which electrolytically infuses a substance into the body tissue upon application of an electric field by the device thereby providing an enhanced and synergistic anti-microbial benefit or improvement to the injury or illness.




2. Description of the Prior Art




Many microorganisms including, but not limited to, virus, bacteria, fungus, etc., exist in the human body. It has been estimated that approximately one-third (⅓) of the United States population harbors pathogenic microorganisms such as several species and strains belonging to the Herpes Simplex family of viruses. The Herpes Simplex family of viruses is responsible for such disease outbreak states as “Cold Sores”. These lesions are often instigated by a systemic malady such as a cold or flu. The lesions can also be provoked by sunlight, emotional stress, and are aggravated by various food substances including caffeine and chocolate.




When an outbreak occurs, the outbreaks occur most frequently around the mouth area and produce large, unsightly, painful sores. During the time that the sore is exposed, the condition is highly contagious and the virus is transmitted readily through both direct contact and indirect contact. Furthermore, the lesions take one (1) to two (2) weeks to heal and occur with a frequency of every few months to every few years, depending on the individual.




To date, there is no known cure for the “Cold Sores” malady. The pathogenic microorganisms that cause the malady, such as Herpes Simplex virus, lay dormant, hiding from the body's natural immune system in the nerve cells until an outbreak occurs. Several therapies have been explored which range from topical antibiotic salves to intravenously administered systemic doses of antibiotics. These therapies have demonstrated only limited success at reducing the duration and severity of a “Cold-Sore” outbreak.




Concerning the treatment of warts, it has been noted that a virus, which lives in the root of the wart, causes warts. The site where the virus lives can actually be one (1 mm) millimeter to two (2 mm) millimeters below the surface of the surrounding tissue. Unfortunately, simply removing or dissolving the tumorous protrusion above the root does not remove the remaining root which still harbors the virus. With conventional treatment methods, eventually, the wart will return.




In the past, iontophoresis machines were constructed to treat warts and other viruses. These machines are very large to treat large areas of tissue and have been nonportable due to their size and required skilled operation by a trained practitioner to achieve the appropriate dose and rate. The conventional iontophoresis machines also required constant monitoring to maintain the desired rate during the procedure.




The conventional iontophoresis machines focus on delivering molecular compounds (drugs) to subcutaneous regions of infected tissue. The drugs are immunomodulators, which cause the T-cells, and K-cells to more actively attack an infection. Some infections like Herpes and warts, hide inside cells during their progeny producing (multiplying) phase and are therefore as resistant to profused antiviral drugs as to the systemically or topically administered versions.




Still other seeming predicate devices give the illusion of antimicrobial action by simply denaturing normal viable cells in the treated region. These devices are less effective and typically render tissue damage due to the medications or the generated free radicals. This tissue damage caused by excessive current density or in some cases the iontophoresis delivery of antiviral drugs, is actually counter productive to the therapy as a whole. A number of virus (particularly the ones producing warts) will remain largely dormant within host cells until the host cell begins to die. This impending death of the host cell triggers the virus to produce progeny, which go on to infect adjacent cells. Thus by killing the host cell, one actually causes the infection to broaden.




Some of the existing systems are so complex or cumbersome as to render them un-useable for anything other than laboratory work. Some previous techniques to fight Herpes required control areas flooded with Methylene Blue and then exposed to a certain wavelength of light. This is only practical in a laboratory environment and is far too sophisticated and expensive for general use. Still other previous systems required large bench-top units which had to be operated by trained personnel and some utilized control pharmaceutical substances which are costly and showed insufficient efficacy to warrant commercialization. Furthermore, pre-existing silver iontophoresis devices offer no or limited control over the dose, rate and penetration.




Therefore, a need exists for a device, which provides an effective treatment for warts by treating the root of the wart through the wart's tumorous protrusion. Additionally, there exists a need for a device, which provides an electrolytic substance infusion device for treating cold sores and other lesions. Furthermore, a need exists for a device, which treats any tissue-based viral, bacterial, or fungal infection through electrolytic substance infusion.




SUMMARY




The present invention is a device for treating an illness or injury of tissue of a body. The device comprises at least a first electrode contactable with the tissue and at least a second electrode contactable with the tissue. A control system is electrically connected to the first electrode and the second electrode with the control system creating an electric field between the first electrode and the second electrode through the body. Silver, acting as an antimicrobial substance is on or comprised of at least a portion of the first electrode with the substance being ionized upon application of the electric field thereby profusing the ionic silver into the tissue.




In another embodiment of the present invention, the substance is selected from the group consisting of any ionic substance including, but not limited to, zinc, copper and silver. Furthermore, preferably, the device treats maladies selected from the group consisting of Herpes-type outbreaks, colds-type maladies, skin cancers, sub-dermal tumors, warts, acne, cold sores, and germicidal or dermatological infections.




The device further comprises an indicator signal for indicating activation of the control system and indication that a satisfactory does is/has been delivered. Furthermore, preferably, the device further comprises an embedded microcontroller or other circuitry for controlling the delivery rate, application waveform and the dose of the silver ions.




In yet another embodiment of the present invention, the device further comprises a small compact housing with the power source positioned within the housing and the first and second electrodes being mounted on the housing.




In another embodiment of the present invention, the microcontroller is activated upon the first and second electrodes contacting the skin. The applied field or waveform is then generated by the embedded microcontroller from the low-voltage battery contained within the box. The microcontroller directly controls the dc/dc switching converter to maintain the desired voltage to produce the optimal infusion rate and waveform.




This completely self-contained auto-turn-on device makes highly effective silver iontophoresis for the treatment of dermatological infections both very portable and very inexpensive.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

is a perspective view illustrating a hand-held device embodiment of the electrolytic substance infusion device, constructed in accordance with the present invention, for treating external skin maladies;





FIG. 2

is a sectional side view illustrating the hand-held device embodiment of the electrolytic substance infusion device of

FIG. 1

, constructed in accordance with the present invention;





FIG. 3

is a perspective view illustrating a bandage device of the electrolytic substance infusion device, constructed in accordance with the present invention, for treating external skin maladies;





FIG. 4

is a sectional side view illustrating the bandage device of the electrolytic substance infusion device of

FIG. 3

, constructed in accordance with the present invention; and





FIG. 5

is a schematic view illustrating the circuitry of the electrolytic substance infusion device, constructed in accordance with the present invention.











DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS




As illustrated in

FIG. 1

, the present invention is an electrolytic substance infusion device, indicated generally at


10


. The infusion device


10


has at least two electrodes


12


having a surface


14


. The electrodes


12


are electrically connected to the infusion device


10


.




As illustrated in

FIG. 2

, the infusion device


10


further has a power source


16


including, but not limited to, a battery, for powering a microcontroller or control system


18


, which generates and applies the electric field between the electrodes


12


. The treatment electrode


12




a


, is comprised of a substance to be administered in an ionic form, or administered in a form that can be either disassociated, mobilized, or affected by means of the small electric field. Examples of the substance covering include, but are not limited to, Zinc, Copper, Silver, etc., since these substances have noted antimicrobial properties. With the substance comprising the surface


14


of the electrode


12




a


, the infusion device


10


of the present invention provides an enhanced and synergistic antimicrobial benefit or improvement by killing or otherwise eliminating microorganisms including, but not limited to, virus, bacteria, fungus, etc. It should be noted that the electrode


12




a


can be constructed from the antimicrobial substance, coated with the antimicrobial substance, and/or used to profuse the antimicrobial substance.




As noted in

FIGS. 1 and 2

, the device does not include wires. A circuit board


17


having a microcontroller


18


which controls the electric field between the metal ion source


12




a


and conducting surface


12




b


is shown. Circuit board


17


also functions to connect the metal ion source


12




a


to the conducting surface


12




b


and microcontroller


18


without the use of wires. Ascrew


15


not only holds the conducting surface


12




b


to the housing or enclosure


13


, but it also enters the circuit board


17


just as threaded end


12




c


of metal ion source


12




a


enters the circuit board. Thus, upon user contacting of the metal ion source


12




a


and the conducting surface


12




b


completes the circuit and the electric field causes the metal ion source


12




a


to be ionized and perfuse metal ions into the user's tissue and the visual indicator


19


to light. The visual indicator


19


is also directly connected to the circuit board


17


.




As illustrated in

FIG. 5

, the infusion device


10


of the present invention contains the small power source


16


including, but not limited to a battery, which when powering the embedded microcontroller


18


to produce the appropriate driving waveform or voltage through the control of the DC/DC converter


20


and applied to the electrodes


12


causes an electric field to be carried through the tissue that is to be treated. The electric field can be any waveform that is advantageous to a particular therapy and can be unipolar or bipolar. An alternating field would serve to move ions from all electrodes


12


. The unipolar field would deliver the substance preferentially from a particular electrode


12


and would drive the substance deeper into the tissue for therapies where subdermal interaction is required. The bipolar field would tend to leave the substance nearer to the skin surface for therapies that warrant a more external application.




Currently, time-release medication patches rely upon diffusion to carry the drug or therapeutic agent into a region producing a natural gradient and requiring high doses at the point of administration in order to deliver acceptable levels at a distance from the contact point. There can also be natural barriers to the diffusion as different tissues can sweep away the substance or block its flow entirely. There is no other effective means for delivering ionic silver subdermally.




With the infusion device


10


of the present invention, when the substance is profused electrolytically and the electrodes


12


are in reasonably close proximity, the electric field mobilizes, drives, or drags the substance through a region to the exit electrode


12


. The electric field also tends to focus the flow of substance and allow a more even distribution as the depth into the tissue increases.




Experimentation by the Applicant of the present application has shown that using an electrode


12


which is comprised of or coated with a silver compound in contact with a lesion, will profuse sufficient ionic silver into a region of tissue to attenuate the viral or bacterial load far more effectively than anti-viral or anti-biotic salves. The infusion device


10


constructed by the inventor using his technique have caused complete remission of HSV lesions, warts, and acne in remarkably short order, e.g., three (3) to five (5) times faster than conventional means. Additionally, infected cuts and scrapes have been rendered infection-free and healing was notably improved.




One of the advantages of using the infusion device


10


of the present invention for treating dermatological infections is that unlike salves, the germicidal effects are profused into the tissue where they remain active and effective for twelve (12) to twenty-four (24) hours. With a salve, the bulk of the agent remains on the surface of the skin and can be easily washed or wiped away during normal daily activities. Additionally, the carrier for the active agent in salves tends to block air access to the tissue prolonging the scabbing and healing process.




VARIOUS PREFERRED EMBODIMENTS OF THE PRESENT INVENTION




The Hand-held Device:




As illustrated in

FIGS. 1 and 2

, the infusion device


10


of the present invention includes a hand-held device


110


providing either an attached electrode


112


, or a free electrodes


112


, positionable and easily moveable about an area to be treated. The electric field is applied and controlled directly by the hand-held device


110


. In this manner, the electrodes


112


are coated with a conductive media, such as a hydrogel, and then are moved about a tissue area to cause the dispersion of a substance into a region, which could not be easily covered with a bandage device.




In one specific embodiment of the hand-held device


110


, as illustrated in

FIG. 6

, the treating electrode


112




a


is composed of a silver compound and a conductive contact


112




b


is provided to complete the circuit. The user simply makes contact to the conductive contact


112




b


with a thumb and holds the treating electrode


112




a


to the area to be treated. The hand-held device


110


then provides a controlled field in order to produce the appropriate dose, rate, and penetration at the electrode


112




a


causing the profusion of the ionic material into the lesion or wound. The hand-held device


110


can be used as a general-purpose germicide treating everything from cuts and scrapes to cold sores, canker sores, warts, and any other dermatological condition, which requires a germicide.




The All Purpose Bandage:




As illustrated in

FIG. 2

, the infusion device


10


of the present invention is a bandage-shaped device


210


containing a small power source


216


, such as a disposable battery or the like. In this embodiment, the infusion device


10


has a main contacting electrode


212




a


comprised of a silver mesh embedded within the bandage device


210


with the return electrode


212




b


contacting the tissue on one side of the wound of the user. The bandage device


210


could be constructed in various shapes and sizes and could be made in varying porosities to permit a desired amount of air to reach the surface of the lesion. The substance administered into the wound could be silver ions or any other antimicrobial agent. The term “antimicrobial agent” means anti-viral, anti-fungal, and anti-bacterial. The power source


216


within the bandage device


210


could be activated prior to use by simply stretching the bandage device


210


. The stretching of the bandage device


110


ruptures the thin polymer sac internal to the power source


216


, which contains the electrolyte for the battery cell. The power source


216


would then become active and provide charge movement for some predetermined period of time based on the design of the bandage device


210


. Alternatively, the control system


218


would sense patient connection as shown in the example schematic when the bandage device


210


is applied, thereby allowing use of a simple battery


216


and inhibiting current flow to the control system


218


and electrodes


212


until the bandage device


210


is applied to the wound.




In the present embodiment, instead of the power source


216


being a battery, the power source


216


could include a capacitor. The capacitor is charged prior to use with a simple charging device containing a battery or other source of power. In the case of a one-hundred (100) microamps current flow, a capacitor of 0.01 Farads provides sufficient current flow for ten (10) minutes when charged to a few volts. Each one hundred (100) microamps-second could, for example, electrolytically profuse approximately 6×10


14


molecules into the tissue. In the case of silver, each microamps-second profuse approximately 1×10


−7


grams of silver ions into the tissue sufficient to treat tissue to a depth of several milliliters.




The generation of the waveforms of the infusion device


10


of the present invention can be controlled by the small microprocessor


18


, such as a PIC12C5XX, requiring less than fifteen (15) microamps to operate. The microprocessor


18


can be procured in die form with dimensions of approximately 0.1 inch×approximately 0.1 inch and for a very low expense, the microprocessor


18


can easily be incorporated into the bandage, patch, or other delivery system as the entire control system can be made smaller than ¼ square inch. With the microprocessor


18


of the infusion device


10


, the actual field strength can be monitored and integrated to allow the delivery of precise amounts of ionic substance at precise rates even though the ohmic contact to the region of interest will vary dramatically.




It should be noted that with the infusion device


10


of the present invention, the actual dose must be correct over a wide range of different tissue impedances. For example, if too much silver is delivered to a region, a brown discoloration will.occur on the skin that generally requires a couple of days to dissipate. If too little silver is delivered to a region, the antimicrobial effect of the silver will not be sufficient to treat the injury or illness. Alternatively, preferably, the electric field can be controlled by use of a constant current source, which is controlled by a fixed component value or profiled and modified by the microcontroller


18


previously described.




The infusion device


10


of the present invention goes beyond the present state of the art to actually deliver ionic silver subdermally, through an electrolytic means to the treatable region of interest. It generates the applied waveform directly from the embedded microcontroller


18


operated dc—dc converter allowing the use of very low voltage power sources such as a common coin type lithium battery. The present invention applies the appropriate dose and rate without any user control. All that is required is for the user to touch it to the treatment site. In doing so, the infusion device


10


inhibits microorganism growth in the specific region of interest thereby inhibiting the need for systemic doses of antibiotics, in many cases. The infusion device


10


of the present invention provides a better and more effective means of treatment for complicated tissues such as “Cold Sore” lesions and tissues that are poorly served by the capillary structure. The required micrograms of substance per milliliter of tissue can be achieved to the depths require to reach the colonies without relying on diffusion and capillary action. The total body-burden of the active agent can be one-hundred (100) to one thousand (1000) times less than what would be expected for systemically administered antibiotics or anti-virals since the dose will be administered directly to the site.




The infusion device


10


of the present invention also allows the construction of bandages, which allow more open-air contact and facilitate rapid skin regeneration in existing wounds or lesions.




Since the infusion device


10


of the present invention causes the profusion of antimicrobial substances through the healthy tissue into a region that is defined by the electrode configuration, the infusion device allows the beneficial effects of the substance to reach an area far greater than that of a simple impregnated device. A simple impregnated conventional device tends by its very nature to only protect the region immediately surrounding the boundary of the device and the tissue. Additionally, a device that is impregnated with an antimicrobial agent tends to hold onto the agent quite well and this renders the germicide far less effective as the virus or bacteria has limited exposure to it. The infusion device


10


of the present invention, on the other hand, provides the smallest possible particles of the agent in an ionic form, which cause it to be readily bound to the germ causing more effective germicidal effects.




Although there are currently available topical salves, which contain antimicrobial substance, the salves rely upon diffusion to reach subcutaneous regions and thus do so rather poorly. The salves tend to be applied so heavily in order to have any effect, that they discolor and kill healthy skin cells. The technique of the present invention of electrolytically profusing substances into the tissue has the significant advantage of requiring far fewer molecules of a substance to achieve the same or higher level of results. Additionally, since the substance is deposited subcutaneously, there is no concern about the amount that is lost to unintended mechanical removal from the surface while the subject is waiting for penetration.




The devices and therapies described herein could be used to combat a range of lesions from cold sores to warts. The infusion device


10


is a completely self-contained totally automatic means for treating infections and cold sores. Unlike conventional devices, the infusion device


10


of the present invention can be produced for low costs and occupies less than a cubic inch. Using the infusion device


10


requires no skill to be used correctly. Its very activation is automatic upon contact with the user's skin.




Also unlike conventional devices, the applied field waveform is dynamically and automatically controlled to optimize the administration of the ionic silver to depths where it can effectively dispatch the colonizing bacteria and proliferating virus. The silver-ion administration that is utilized in the present invention overcomes these shortcomings by acting directly on inhibiting the virus without requiring the support of the immune system in order to inactivate or destroy. Additionally, due to the single atom ionic nature of the present invention, the anti-microbial silver ions pass through the cell walls of the infected tissue destroying the virus while they remain hidden.




The infusion device


10


utilizes silver ions, which move freely across the peptidechain cell walls and disable the virus without killing the host thereby far more effectively terminating an infection or a viral outbreak. The infusion device


10


offers this control automatically via a pre-programmed response to the dynamically changing tissue impedance and waveform control to facilitate penetration. By controlling the dose rate and dose automatically as the tissue impedance changes, no user insight or understanding is required. The ability to produce the necessary voltages and waveforms from small and inexpensive batteries within a compact, inexpensive and rugged device places this novel and effective therapy in the hands of the general population. Rendering this terrific germicidal activity simply and cost effectively without the use of drugs, obviates the need for professional supervision and brings this therapy to a population of far greater number than predicate devices which are all focused on transdermal drug delivery. By directly generating the applied voltage under microcontroller control, the infusion device


10


offers far more efficient battery use prolonging system life. Additionally, this control allows more flexibility in the applied waveforms.




The foregoing exemplary descriptions and the illustrative preferred embodiments of the present invention have been explained in the drawings and described in detail, with varying modifications and alternative embodiments being taught. While the invention has been so shown, described and illustrated, it should be understood by those skilled in the art that equivalent changes in form and detail may be made therein without departing from the true spirit and scope of the invention, and that the scope of the present invention is to be limited only to the claims except as precluded by the prior art. Moreover, the invention as disclosed herein, may be suitably practiced in the absence of the specific elements, which are disclosed herein.



Claims
  • 1. A portable hand-held device for treating an illness or infection of tissue of a body, the device comprising:a housing; a metal ion source mounted on the exterior of the housing which is directly contactable with the tissue; a conducting surface mounted on the exterior of the housing which is contactable with the user; an automatically controlled and modulated field electrically connected to the metal ion source and the conducting surface automatically activated upon the metal ion source contacting the tissue and the conducting surface contacting the user; wherein an electric field is created between the metal ion source and the conducting surface through the body such that the electric field causes the metal ion source to be ionized and perfuse metal ions into the tissue.
  • 2. The device of claim 1 wherein the metal ion source is selected from a group of ionizable materials including zinc, copper and silver.
  • 3. The device of claim 1 further comprising an indicator signal for indicating activation of the electric field and correct delivery of a selected dose and dose rate.
  • 4. The device of claim 1 wherein the device treats maladies selected from the group consisting of Herpes-type outbreaks, warts, acne, cold sores, and germicidal on dermatological infections.
  • 5. The device of claim 1 further comprising circuitry for controlling the delivery rate of the metal ions, dose of the metal ions, waveform, and voltage.
  • 6. The device of claim 1 further comprising a power source positioned within the housing and a control system mounted within the housing which automatically controls and modulates the electric field.
  • 7. The device of claim 6 wherein the control system includes a controllable DC-to-DC converter to generate the required voltages and waveforms from a single cell battery to operate the device.
  • 8. The device of claim 1 wherein the electric field is a bipolar field at low frequencies for maintaining a surface only distribution of the metal ions.
  • 9. The device of claim 1 further comprising a microcontroller which controls the electric field between the metal ion source and conducting surface and a circuit board which connects the metal ion source to the conducting surface and microcontroller without the use of wires.
  • 10. A completely self-contained disposable bandage device for treating an illness or infection of tissue of a body, the bandage device comprising:an adhesive strip; a metal ion source mounted on the adhesive strip which is directly contactable with the tissue when the adhesive strip is secured to a user; a conducting surface mounted on the adhesive strip which is contactable with the user when the adhesive strip is secured to the user; an automatically controlled and modulated field electrically generating system attached to the adhesive strip and connected to the metal ion source and the conducting surface which is automatically activated upon the metal ion source contacting the tissue and the conducting surface contacting the user skin proximate the tissue; wherein an electric field is created between the metal ion source and the conducting surface through the body such that the electric field causes the metal ion source to be ionized and perfuse metal ions into the tissue.
  • 11. The device of claim 10 wherein the metal ion source is selected from a group consisting of ionizable materials including zinc, copper and silver.
  • 12. The device of claim 10 further comprising an indicator signal for indicating activation of the electric field and correct delivery of a selected dose and dose rate.
  • 13. The device of claim 10 wherein the device treats maladies selected from the group consisting of Herpes-type outbreaks, warts, acne, cold sores, and germicidal on dermatological infections.
  • 14. The device of claim 10 further comprising circuitry for controlling the delivery rate of the metal ions, dose of the metal ions, waveform, and voltage.
  • 15. The device of claim 10 further comprising a power source positioned within the bandage and a control system positioned within the bandage which automatically controls and modulates the electric field.
  • 16. The device of claim 15 wherein the control system includes a controllable DC-to-DC converter to generate the required voltages and waveforms from a single cell battery to operate the device.
  • 17. The device of claim 10 wherein the electric field is a bipolar field at low frequencies for maintaining a surface only distribution of the metal ions.
  • 18. A method of infusing an antimicrobial metal ion into tissue of a body, the method comprising:providing at least an antimicrobial metal ion source; providing a contact surface; contacting the tissue with metal ion source and the contact surface; ionizing the antimicrobial metal ion source; and infusing the antimicrobial metal ions into the tissue applying an adhesive to the device to form a bandage strip and releasably securing the bandage strip to the tissue such that the antimicrobial metal ion source is in direct contact therewith.
  • 19. The method of claim 18 further comprising providing an embedded microcontroller attached to the bandage strip and supporting circuitry for automatically controlling the delivery rate of the metal ions, dose of the metal ions, waveform, and voltage.
  • 20. A portable hand-held device for treating an illness or infection of tissue of a body at a selected dose and dose rate of metal ions, the device comprising:a housing with a visual indicator light thereon; a metal ion source mounted on the housing which is directly contactable with the tissue; a conducting surface mounted on the housing which is contactable with the user; an automatically controlled and modulated field electrically connected to the metal ion source and the conducting surface automatically activated upon the metal ion source contacting the tissue and the conducting surface contacting the user; wherein an electric field is created between the metal ion source and the conducting surface through the body such that the electric field causes the metal ion source to be ionized and perfuse metal ions into the tissue and activate the indicator light only upon determining that the selected dose and dose rate of metal ions is correct.
  • 21. The device of claim 20 further comprising a microcontroller which controls the electric field between the metal ion source and conducting surface and a circuit board which connects the metal ion source to the conducting surface and microcontroller without the use of wires.
Parent Case Info

The present application is a continuation of patent application Ser. No. 09/182,581, filed on Oct. 29, 1998, entitled “Electrolytic Substance Infusion Device” now abondoned.

US Referenced Citations (22)
Number Name Date Kind
3831598 Tice Aug 1974 A
3918459 Horn Nov 1975 A
3964477 Ellis et al. Jun 1976 A
4305390 Swartz Dec 1981 A
4411648 Davis et al. Oct 1983 A
4474570 Ariura et al. Oct 1984 A
4774833 Weibler et al. Oct 1988 A
4808152 Sibalis Feb 1989 A
4821700 Weibler et al. Apr 1989 A
5254081 Maurer et al. Oct 1993 A
5306287 Becker Apr 1994 A
5322520 Milder Jun 1994 A
5328451 Davis et al. Jul 1994 A
5498248 Milder Mar 1996 A
5571149 Liss et al. Nov 1996 A
5676648 Henley Oct 1997 A
5749845 Hildebrand et al. May 1998 A
5805423 Wever et al. Sep 1998 A
5846217 Beck et al. Dec 1998 A
5865787 Shapland et al. Feb 1999 A
6001088 Roberts et al. Dec 1999 A
6175763 Sorenson et al. Jan 2001 B1
Continuations (1)
Number Date Country
Parent 09/182581 Oct 2001 US
Child 09/718521 US